Live Breaking News & Updates on Investigator Assessed

Stay updated with breaking news from Investigator assessed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Daiichi Sankyo and AstraZeneca’s ENHERTU showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population

Results reaffirm. ....

United States , Daiichi Sankyo , Cristian Massacesi , Mark Rutstein , Merck Co Inc , National Cancer Institute , American Society Of Clinical Oncology , Oncology Clinical Development , European Society For Medical Oncology , University Of Texas Md Anderson Cancer Center , Clinical Development Program , Daiichi Sankyo Inc , European Society , Medical Oncology , Clinical Oncology , Funda Meric Bernstam , Investigational Cancer Therapeutics , Cancer Center , Principal Investigator , Global Head , Chief Medical Officer , Oncology Chief Development Officer , Investigator Assessed , Lung Disease , Breast Cancer , Metastatic Gastric Cancer ,

ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors

Daiichi Sankyo and AstraZeneca’s ENHERTU showed an objective response rate of 37.1% in the overall population of the DESTINY-PanTumor02 phase 2 trial

ENHERTU is the first therapy to show. | June 5, 2023 ....

United States , Cristian Massacesi , Daiichi Sankyo , Mark Rutstein , Department Of Investigational Cancer Therapeutics , Clinical Development Program , University Of Texas Md Anderson Cancer Center , Oncology Development , Sarah Cannon Research Institute , Daiichi Sankyo Inc , American Society Of Clinical Oncology , Clinical Oncology , Funda Meric Bernstam , Investigational Cancer Therapeutics , Cancer Center , Principal Investigator , Global Head , Chief Medical Officer , Oncology Chief Development Officer , Investigator Assessed , Sarah Cannon Research , Lung Disease , Breast Cancer , Metastatic Gastric Cancer , Absolute Neutrophil Count , Fetal Toxicity ,